4D Molecular Therapeutics, Inc.FDMTNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -99.99% | +0.00% | -50.00% | +200.00% | +2900.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | -1571700.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +31.47% | +37.86% | +13.14% | +1.17% | +1.03% |
| Weighted Average Shares Diluted Growth | +31.47% | +37.86% | +13.14% | +1.17% | +1.03% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +67.04% | +64.87% | -18.12% | -23.62% | -29.81% |
| Book Value per Share Growth | +27.48% | +20.32% | -30.87% | -29.29% | -33.95% |
| Debt Growth | +63.85% | +67.72% | +68.32% | +68.99% | -10.35% |
| R&D Expense Growth | +53.53% | +65.53% | +46.03% | +50.51% | +28.46% |
| SG&A Expenses Growth | +38.84% | +37.93% | +25.67% | +8.67% | -6.43% |